title: A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer.
abstract: The aim of the current study was to determine the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of a combination of paclitaxel and S-1 in patients with advanced gastric cancer. Fifteen patients were enrolled. The dose for S-1 was set at 80 mg/m2/day (days 1-14), while the dose for paclitaxel increased by 10 mg/m2 for every three patients, with a starting dose of 100 mg/m2 and was given biweekly on day 1 and 15. There was no severe toxicity (grade 4) recorded in patients receiving up to 120 mg/m2 of paclitaxel. Leukopenia/neutrophilia with grade 1 to 3 occurred in six patients up to level 3. At 130 mg/m2 of paclitaxel, grade 4 leukocytopenia and neutropenia events and grade 3 diarrhea developed in one out of three patients. One patient in another group of three patients that were enrolled at level 3, developed grade 4 granulocytopenia with fever (a body temperature higher than 38 degrees C) and grade 3 leukocytopenia. Eight patients, out of a total of 15, showed a partial response, resulting in an objective response rate of 53%. Five patients received gastrectomy. Median survival time was 428 days and the 1 year survival rate was 53%. Biweekly paclitaxel/S-1 combination chemotherapy could be safely used for the treatment of advanced gastric cancer. The recommended doses for a phase II study with paclitaxel and S-1 are 120 mg/m2 and 80 mg/m2, respectively.
authors.affiliation: First Department of Surgery School of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 8900075, Japan. hokita@m2.kufm.kagoshima-u.ac.jp
authors.forename: Shuichi
authors.initials: S
authors.lastname: Hokita
authors.forename: Takashi
authors.initials: T
authors.lastname: Aikou
authors.forename: Futoshi
authors.initials: F
authors.lastname: Miyazono
authors.forename: Sumiya
authors.initials: S
authors.lastname: Ishigami
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Aridome
authors.forename: Shigeho
authors.initials: S
authors.lastname: Maenohara
authors.forename: Tetsushi
authors.initials: T
authors.lastname: Saihara
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Suenaga
authors.forename: Hidehiro
authors.initials: H
authors.lastname: Nomura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Maeda
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takatori
authors.forename: Hideo
authors.initials: H
authors.lastname: Arima
authors.forename: Yasuto
authors.initials: Y
authors.lastname: Uchikado
authors.forename: Shoji
authors.initials: S
authors.lastname: Natsugoe
authors.forename: Sonshin
authors.initials: S
authors.lastname: Takao
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects; D013274:Stomach Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel